Sucralfate

Generic name
Sucralfate
Brand name
ATC Code
A02BX02
Compare …

Sucralfate

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Sucralfat is only minimally absorbed from the GI-tract [SmPC].

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Reflux oesophagitis, prophylaxis of stress ulcers and recurrent ulcers
  • Oral
    • 1 year up to 3 years
      • 0.25 g/dose, as required, max. 6x daily.
    • 3 years up to 10 years
      • 0.5 g/dose, as required, max. 6x daily.
    • 10 years up to 18 years
      • 1 g/dose, as required, max. 6x daily.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Dose adjustment not needed
GFR 30-50 ml/min/1.73 m2
Dose adjustment not needed
GFR 10-30 ml/min/1.73 m2
Avoid long-term use because of the risk of encephalopathy from accumulation of absorbed aluminum.
GFR < 10 ml/min/1.73 m2
A general recommendation is not provided

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Bezoar formation has been reported in newborns after sucralfate administration. In premature neonates, aluminium accumulation in the bones was observed [SmPC].

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

H2-receptor antagonists
A02BA01
A02BA03
A02BA02
Proton pump inhibitors
A02BC05
A02BC01
A02BC02
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
A02BX13

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Daschner, M, Tabellarium Nephrologicum, Dosierungs- und Therapieschemata bei pädiatrischer Niereninsuffizienz, 3. Auflage, Shaker Verlag, Aachen, 2009
  3. Genericon, SmPC Sucralfat Genericon 1 g/5 ml orale Susp. (1-20571), 03/2018

Changes

Therapeutic Drug Monitoring


Overdose